| # | Title | Journal | Year | Citations |
|---|
| 1 | The role of BRAF V600 mutation in melanoma | Journal of Translational Medicine | 2012 | 563 |
| 2 | Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database | Journal of Clinical Oncology | 2007 | 488 |
| 3 | Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma | Blood | 2007 | 413 |
| 4 | Chordoma: The Nonsarcoma Primary Bone Tumor | Oncologist | 2007 | 342 |
| 5 | DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies | Leukemia | 2014 | 225 |
| 6 | The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer | Oncologist | 2007 | 218 |
| 7 | Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management | Scientifica | 2013 | 186 |
| 8 | Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program | Clinical Lung Cancer | 2005 | 174 |
| 9 | Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients | Clinical Cancer Research | 2016 | 166 |
| 10 | Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 | Blood | 2006 | 141 |
| 11 | The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations | Oral Oncology | 2016 | 141 |
| 12 | Cutaneous melanoma: available therapy for metastatic disease | Dermatologic Therapy | 2006 | 121 |
| 13 | The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage | British Journal of Haematology | 2007 | 118 |
| 14 | Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b | Clinical Cancer Research | 2007 | 110 |
| 15 | The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement | Clinical Cancer Research | 2013 | 110 |
| 16 | Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors | Neuro-Oncology | 2016 | 101 |
| 17 | A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma | Cancer | 2009 | 96 |
| 18 | Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity | Blood | 2012 | 95 |
| 19 | Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma | Clinical Cancer Research | 2006 | 94 |
| 20 | IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM | Blood | 2011 | 89 |
| 21 | Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer | Proceedings of the National Academy of Sciences of the United States of America | 2014 | 86 |
| 22 | Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer | Expert Review of Anticancer Therapy | 2003 | 85 |
| 23 | Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype | Cancer Discovery | 2015 | 82 |
| 24 | You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia | Leukemia | 2015 | 77 |
| 25 | Programmed death-1 checkpoint blockade in acute myeloid leukemia | Expert Opinion on Biological Therapy | 2015 | 75 |
| 26 | Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia | Blood | 2010 | 74 |
| 27 | Regulation of Reactive Oxygen Species Homeostasis by Peroxiredoxins and c-Myc | Journal of Biological Chemistry | 2009 | 73 |
| 28 | C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells | Blood | 2009 | 73 |
| 29 | Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response | Clinical Cancer Research | 2020 | 72 |
| 30 | Activation of Human Mesenchymal Stem Cells Impacts Their Therapeutic Abilities in Lung Injury by Increasing Interleukin (IL)-10 and IL-1RN Levels | Stem Cells Translational Medicine | 2013 | 70 |
| 31 | Hierarchy of α Fetoprotein (AFP)-Specific T Cell Responses in Subjects with AFP-Positive Hepatocellular Cancer | Journal of Immunology | 2006 | 67 |
| 32 | Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer | Annals of Oncology | 2013 | 65 |
| 33 | Effect of a proton pump inhibitor on the pharmacokinetics of imatinib | British Journal of Clinical Pharmacology | 2009 | 58 |
| 34 | Rare Event Detection and Analysis in Flow Cytometry: Bone Marrow Mesenchymal Stem Cells, Breast Cancer Stem/Progenitor Cells in Malignant Effusions, and Pericytes in Disaggregated Adipose Tissue | Methods in Molecular Biology | 2011 | 55 |
| 35 | Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary report | Cancer | 2017 | 55 |
| 36 | SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth | Blood | 2007 | 53 |
| 37 | Assessing oncologic benefit in clinical trials of immunotherapy agents | Annals of Oncology | 2010 | 51 |
| 38 | AFP-specific CD4+ Helper T-cell Responses in Healthy Donors and HCC Patients | Journal of Immunotherapy | 2007 | 50 |
| 39 | Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and Liver | American Journal of Clinical Pathology | 2016 | 50 |
| 40 | Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer | Breast Cancer Research | 2011 | 49 |
| 41 | Immunotherapeutic Approaches to Sarcoma | Current Treatment Options in Oncology | 2015 | 48 |
| 42 | Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions | Cancer | 2012 | 47 |
| 43 | Novel targets in the treatment of chronic graft-versus-host disease | Leukemia | 2017 | 47 |
| 44 | Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer | Journal of Translational Medicine | 2018 | 47 |
| 45 | Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro | Leukemia Research | 2012 | 45 |
| 46 | Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant | Leukemia and Lymphoma | 2008 | 42 |
| 47 | The Neural Stem Cell Fate Determinant TLX Promotes Tumorigenesis and Genesis of Cells Resembling Glioma Stem Cells | Molecules and Cells | 2010 | 42 |
| 48 | Dysregulated phosphatidylinositol signaling promotes endoplasmic-reticulum-stress-mediated intestinal mucosal injury and inflammation in zebrafish | DMM Disease Models and Mechanisms | 2014 | 41 |
| 49 | Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies | Clinical Pharmacology and Therapeutics | 2009 | 40 |
| 50 | Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole | Oncotarget | 2017 | 40 |
